search results for

refine results

sort by


result type


Press Releases

Fed statements lack consistency: Deutsche AM CIO

The Fed will hold off on tightening policy on the back of Brexit and presidential election risks, says Sean Taylor, APAC CIO of Deutsche Asset Management.


Maersk: Not satisfied with earnings

While the company's first quarter results were as expected, Robbert Van Trooijen, APAC CEO of Maersk Line explains which business areas need more progress.


JPM: Expect oil prices to soften in the near-term

JPMorgan's APAC oil, gas and chemicals research head Scott Darling gives his take on the beleaguered energy industry.


Santos Q1 production rises 11% on-year

Santos is finally in the right stage of their investment cycle versus a year ago, explains Craig McMahon, APAC head of research at Wood Mackenzie.


Is Spotify on track with APAC ambitions?

Sunita Kaur, Asia-Pacific MD for Spotify, tells CNBC how the music streaming app is modified to cater to individual markets in the region.


Pictet WM: Market rules have changed

Claude Haberer, Pictet Wealth Management APAC CEO, advises investors to have market-neutral strategies amid an environment of market uncertainty.


'Seeing broad-based recovery in China property'

State-owned enterprises, such as China Overseas Land, are well-placed to benefit from current government policy, notes Wee Liat Lee, head of APAC property research at BNP Paribas.


JPM: BOJ opened the trapdoor of negative rates

Negative interest rates are having a negative effect on the markets, creating a problem for the central bank, says Richard Titherington, CIO and head of EM and APAC equities at JPMorgan Asset Management


Too much red tape in cancer therapies?

Access, diagnostics and the quality of cancer care are challenges in developing countries, warns Dr Masum Hossain, APAC regional president and managing director of Pfizer Oncology.


Pfizer's cancer immunotherapy push

Dr Masum Hossain, APAC regional president and managing director of Pfizer Oncology, explains why immunotherapy is a priority for the pharmaceutical firm, especially in Asia.